Clinical observation on recombinant human thrombopoietin for treatment of concurrent chemoradiation-induced thrombocytopenia in solid tumor patients

Chen Bo,Li Tao,Zhang Jun,Huang Dandan,Sun Changjin,Wang Liyang,Ma Jiabao,Wei Yang

DOI: https://doi.org/10.3969/j.issn.1672-1535.2012.02.003

2012-01-01

Abstract:Objective To evaluate the efficacy and safety of recombinant human thrombopoietin(rhTPO) in the treatment of concurrent chemoradiation-induced thrombocytopenia with solid tumor.Methods Thirty-eight patients with platelet count<50×109/L after concurrent chemoradiation received subcutaneous injection of rhTPO,then the characteristics of PLT count reductions,therapeutic effect and side-effect were analyzed.Results The thrombocytopenia with solid tumor often happened in(5.2±1.9) d after concurrent chemoradiation.The minimal PLT count after concurrent chemoradiation was related to the radiation volume in treatment.The patients with radiation volume ≥50% in breastbone or pelvis took longer time to recover PLT count.It was found that the time of PLT count to recover to be more than 75×109/L and 100×109/L after concurrent chemoradiation was(6.1±2.4) d and(7.9±2.5) d,respectively.There were seven patients who needed PLT transfusion.The side-effect(muscle and joint aches) rate was 7.9%.Conclusion The thrombocytopenia will be more obvious and last longer when patients with solid tumor receive concurrent chemoradiation,especially those who with radiation volume ≥50% in breastbone or pelvis..rhTPO is capable of reducing the degree and duration of thrombocytopenia significantly as promoting PLT recovery without severe side-effect for patients with solid tumor after concurrent chemoradiation.